Spanish regulator authorises phase III trials of Hipra’s Covid vax

Spain’s medicines agency said on Tuesday it had authorized pharmaceutical company Hipra to conduct phase III trials of the COVID-19 vaccine it is developing.

Phase III is the final round of testing before seeking marketing authorization for a drug.

Hipra began phase II trials in November which involved testing the vaccine in 1,000 volunteers at ten hospitals in Spain.

Hipra said on its website that it expects to be able to produce 600 million doses in 2022 and to double that figure the following year. Reuters